assembly Bill A1055

2023-2024 Legislative Session

Relates to the availability of buprenorphine in opioid treatment programs

download bill text pdf

Sponsored By

Current Bill Status - In Assembly Committee

  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

Your Voice

do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

view actions (2)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Apr 25, 2023 reported referred to ways and means
Jan 13, 2023 referred to alcoholism and drug abuse

A1055 (ACTIVE) - Details

See Senate Version of this Bill:
S3347
Law Section:
Mental Hygiene Law
Laws Affected:
Add §32.12, Ment Hyg L
Versions Introduced in Other Legislative Sessions:
2019-2020: A5953
2021-2022: A705, S6746

A1055 (ACTIVE) - Summary

Requires facilities that provide treatment for substance use disorders to have at least one practitioner qualified to administer or prescribe buprenorphine to individuals in their care with substance use disorders related to opioids.

A1055 (ACTIVE) - Bill Text download pdf 

 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   1055
 
                        2023-2024 Regular Sessions
 
                           I N  A S S E M B L Y
 
                             January 13, 2023
                                ___________
 
 Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
   Committee on Alcoholism and Drug Abuse
 
 AN ACT to amend the mental hygiene law, in relation to the  availability
   of buprenorphine in opioid treatment programs
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The mental hygiene law is amended by adding a  new  section
 32.12 to read as follows:
 § 32.12 AVAILABILITY OF BUPRENORPHINE.
   EVERY   FACILITY  LICENSED  OR  AUTHORIZED  TO  PROVIDE  SERVICES  FOR
 SUBSTANCE USE DISORDERS RELATED TO  OPIOIDS  THAT  EMPLOYS  A  QUALIFIED
 PRACTITIONER,  AS  DETERMINED  BY FEDERAL LAW, SHALL ENSURE AT LEAST ONE
 PRACTITIONER IN THE FACILITY HAS RECEIVED AN APPROPRIATE  WAIVER  AND/OR
 HAS COMPLETED REQUIRED TRAINING TO ADMINISTER OR PRESCRIBE BUPRENORPHINE
 TO  INDIVIDUALS  IN  THEIR CARE WITH A SUBSTANCE USE DISORDER WHERE SUCH
 DRUG IS DETERMINED APPROPRIATE FOR THEIR TREATMENT.
   § 2. This act shall take effect on the one hundred twentieth day after
 it shall have become a law.  Effective immediately, the addition, amend-
 ment and/or repeal of any rule or regulation necessary for the implemen-
 tation of this act on its effective date are authorized to be  made  and
 completed on or before such effective date.
 
 
 
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD00691-01-3